logo
  Join        Login             Stock Quote

Pfizer (PFE) 3Q Earnings Drop As Lipitor Weighs On Revenue, Narrows Forecast

 November 01, 2012 07:25 AM
 


(By Balachander) Pfizer Inc. (NYSE: PFE) posted a fall in quarterly earnings as loss of exclusivity of cholesterol drug Lipitor in the U.S. continued to hurt results and the pharma giant narrowed its forecast for the full year.

Adjusted earnings per share (EPS) declined 12 percent to 53 cents from 60 cents, matching market expectations.

Reported earnings dropped 14 percent to $3.21 billion. Results primarily included a $491 million charge resulting from an agreement with the U.S. Department of Justice to resolve a probe into Wyeth's historical promotional practices in connection with Rapamune.

Revenue was $13.98 billion, down 16 percent from $16.61 billion, while analysts expected $14.64 billion. U.S. revenue fell 18 percent, while International revenue declined 14 percent due to the unfavorable impact of foreign exchange.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

"Overall, our results this quarter reflect continued product losses of exclusivity, most notably Lipitor in all major markets," commented CEO Ian Read.

The New York-based pharmaceutical giant's U.S. branded Lipitor revenue tumbled 71 percent for the third quarter. Lipitor lost exclusivity in the U.S. in November 2011 and other markets in 2011 and 2012. This loss of exclusivity reduced branded worldwide revenue by $1.9 billion in the third quarter.

Cost of sales fell 22 percent. Selling, informational and administrative expenses and research and development expenses dropped 14 percent and 9 percent, respectively.

[Related -Six Stocks That Could Get An October Bump From The FDA]

Looking ahead for the full year, the company now forecasts adjusted EPS in the range of $2.14 to $2.17 on revenue between $58.0 billion and $59.0 billion. Analysts expect EPS of $2.21 on revenue of $59.47 billion. Earlier, Pfizer guided adjusted EPS of $2.12 to $2.22 on revenue of $58.0 billion and $60.0 billion.

In addition, the company has authorized a new $10 billion share buyback plan, upon the sale of the Nutrition(1) business to Nestle, which is now expected to be completed in the next few months.

The stock, which has been trading in the 52-week range between $18.15 and $26.09, ended Wednesday's regular trading at $24.87.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageLadenburg Thalmann Financial Services (NYSEMKT:LTS): Heavy, Durable Insider Buying

Ahh, but any worries over price levels didn’t stop multiple insiders at Ladenburg Thalmann Financial read on...

article imageInternational Business Machines Corp. (IBM) Q2 Earnings Preview: Small Beat and Pop

International Business Machines Corp. (NYSE:IBM) will host a conference call Wednesday, Jul. 16, 2014 at read on...

article imageGoogle Inc. (GOOGL) Q2 Earnings Preview: A Few Pennies Either Way Make a Big Difference.

Google Inc. (NASDAQ:GOOGL) will hold its quarterly conference call to discuss second quarter 2014 financial read on...

article image19 Companies That Could Beat Earnings and Pop on Price Next Week

Using iStock’s proprietary iEstimates model, we have identified 19 publicly traded companies that could read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.